Clinical Research on Type 2 Diabetes and Its Complications

The huge prevalence of type 2 diabetes is a leading human and economic concern worldwide. The diagnosis code of type 2 diabetes includes multiple clinical phenotypes showing different degrees of obesity, fat distribution patterns, types of dyslipidemia, and characteristics of insulin resistance synd...

Full description

Bibliographic Details
Format: eBook
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:
CVD
n/a
sex
Online Access:Open Access: DOAB: description of the publication
Open Access: DOAB, download the publication
LEADER 06166namaa2201609uu 4500
001 doab128833
003 oapen
005 20231130
006 m o d
007 cr|mn|---annan
008 231130s2023 xx |||||o ||| 0|eng d
020 |a 9783036594187 
020 |a 9783036594194 
020 |a books978-3-0365-9419-4 
024 7 |a 10.3390/books978-3-0365-9419-4  |2 doi 
040 |a oapen  |c oapen 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
720 1 |a Gómez-Peralta, Fernando  |4 edt 
720 1 |a Gómez-Peralta, Fernando  |4 oth 
245 0 0 |a Clinical Research on Type 2 Diabetes and Its Complications 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2023 
300 |a 1 online resource (322 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |f Unrestricted online access  |2 star 
520 |a The huge prevalence of type 2 diabetes is a leading human and economic concern worldwide. The diagnosis code of type 2 diabetes includes multiple clinical phenotypes showing different degrees of obesity, fat distribution patterns, types of dyslipidemia, and characteristics of insulin resistance syndrome. In addition, subjects with type 2 diabetes could develop different clinical trajectories, with age being a critical factor in progression. The chronic complications of type 2 diabetes are a major cause of mortality and disability, and are ranked in the top places in western countries' scores. The pathophysiological heterogeneity of type 2 diabetes is not captured by the current classifications and guidelines. The potential for diabetes progression and complications developing is different depending on the type 2 diabetes cluster, which is mostly regardless of the degree of glycemic control. However, the impact on quality and life expectancy with the current therapeutic approach is not always the same for every individual. Clinical research is the key to reducing the burden of diabetes. New basic, digital, and clinical approaches are obtaining useful knowledge and designing more individualized interventions to prevent, track, and treat diabetic complications. This Special Issue is a clear reflection of this methodological evolution. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |u https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine and Nursing  |2 bicssc 
653 |a acarbose 
653 |a advanced glycation end products 
653 |a alpha-glucosidase inhibitors 
653 |a ambulatory care 
653 |a behaviour change intervention 
653 |a blood glucose monitoring 
653 |a body weight 
653 |a bone fragility 
653 |a bone quality 
653 |a bone structure 
653 |a cardiac autonomic neuropathy 
653 |a cardiac fibrosis 
653 |a cardiovascular complications 
653 |a cardiovascular disease 
653 |a cardiovascular diseases 
653 |a chemotaxis 
653 |a co-design 
653 |a comorbidities 
653 |a comorbidity 
653 |a complex intervention 
653 |a concomitant drugs 
653 |a continuity of care 
653 |a coronavirus infections 
653 |a COVID-19 
653 |a CVD 
653 |a depression 
653 |a developing country 
653 |a diabetes 
653 |a diabetes complications 
653 |a diabetes mellitus 
653 |a diabetic nephropathy 
653 |a diabetic peripheral neuropathy 
653 |a diabetic retinopathy 
653 |a diabetic sensorimotor polyneuropathy 
653 |a dipeptidyl peptidase-4 inhibitor 
653 |a electrophysiology 
653 |a empagliflozin 
653 |a end-stage kidney disease 
653 |a endothelial cells 
653 |a Ethiopia 
653 |a fibrosis 
653 |a fracture risk 
653 |a gender 
653 |a glucagon-like peptide-1 receptor agonist 
653 |a glucose transport 
653 |a glucose variability 
653 |a glycemic control 
653 |a HbA1c 
653 |a hospitalization 
653 |a hyperglycemia 
653 |a hypoglycemia 
653 |a hypoglycemic agents 
653 |a immunosuppressants 
653 |a in-hospital mortality 
653 |a Korean National Health Insurance Corporation 
653 |a liraglutide 
653 |a machine learning 
653 |a meta-analysis 
653 |a microvascular complications 
653 |a miglitol 
653 |a monocytes 
653 |a n/a 
653 |a NAFLD 
653 |a NASH 
653 |a nephropathy 
653 |a non-alcoholic fatty liver disease 
653 |a non-alcoholic steatohepatitis 
653 |a obesity 
653 |a obesity and diabetes mellitus type 2 
653 |a patient participation 
653 |a patient profiles 
653 |a patient transfer 
653 |a pneumatosis intestinalis 
653 |a poststroke complications 
653 |a prediction 
653 |a prednisone 
653 |a primary care 
653 |a progression 
653 |a pulse wave velocity 
653 |a random forest 
653 |a reactive oxygen species (ROS) 
653 |a readmission 
653 |a real-world evidence 
653 |a research 
653 |a risk factors 
653 |a screening 
653 |a secondary care 
653 |a semaglutide 
653 |a sex 
653 |a SGLT-2 
653 |a skin autofluorescence 
653 |a stroke outcome 
653 |a SURE study 
653 |a telemedicine 
653 |a type 2 
653 |a type 2 diabetes 
653 |a type 2 diabetes mellitus 
653 |a urine albumin-creatinine ratio 
653 |a vascular dysfunction 
653 |a VEGFR-1 
653 |a VEGFR-2 
653 |a voglibose 
793 0 |a DOAB Library. 
856 4 0 |u https://directory.doabooks.org/handle/20.500.12854/128833  |7 0  |z Open Access: DOAB: description of the publication 
856 4 0 |u https://mdpi.com/books/pdfview/book/8303  |7 0  |z Open Access: DOAB, download the publication